Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE Cameron Associates
-- Brainsway Pioneers Novel Treatment for Broad Range of Brain Disorders
-- Report Available for Download at http://www.cameronassoc.com/client-research3.html
NEW YORK, Dec. 12, 2013 /PRNewswire/ -- Cameron Associates, Inc., a provider of investor relations services to public companies since 1976, today announced that it has initiated coverage of Brainsway Ltd. (TASE: BRIN), a medical technology company that leverages long-accepted transcranial magnetic stimulation (TMS) technology to pioneer a novel, non-invasive, cost effective and reimbursable therapy in an outpatient setting for a broad range of brain disorders. An excerpt from the full 41 page Initiation Report follows below and is available to download at the Cameron Associates website at http://www.cameronassoc.com/client-research3.html
Non-invasive, Clinically Effective Deep TMS Therapy for Depression is But a Start
About Cameron Associates, Inc.
Cameron Associates, founded in 1976, provides strategic counsel to companies that need guidance in achieving key business goals, such as improved visibility and reputation in the equity markets, proper positioning of complex financial transactions, and communicating critical corporate issues. We have earned the respect of the Street and have built long-lasting relationships due to our ability to deliver consistently reliable and credible investor relations and capital markets advice to our clients.
For more information, please visit: www.cameronassoc.com
The research report described in this press release is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell securities. The securities discussed in Cameron Associates research reports may be unsuitable for some investors depending on their specific investment objectives, financial status, risk profile, or particular needs. Investors should consider Cameron Associates reports as only a single factor in making their investment decisions and should not rely solely on these reports in evaluating whether or not to buy or sell the securities of the subject company. Cameron Associates has been compensated by the company that is the subject of the report described and future research reports and investor relations services. Please read the reports full disclosures on the Cameron Associates website, www.cameronassoc.com, before investing. Cameron Associates is not a registered investment adviser or broker-dealer.
This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. These forward-looking statements represent Cameron Associates judgment as of the date of this release. Cameron Associates disclaims, however, any intent or obligation to update these forward-looking statements.
©2012 PR Newswire. All Rights Reserved.